Immune response to antigen adsorbed to aluminum hydroxide particles: Effects of co‐adsorption of ALF or ALFQ adjuvant to the aluminum‐antigen complex
暂无分享,去创建一个
Z. Beck | G. Matyas | C. Alving | D. Lanar | Carl R Alving | Zoltan Beck | Gary R Matyas | David E Lanar | Oscar B Torres | Oscar B. Torres
[1] M. Kundi. New hepatitis B vaccine formulated with an improved adjuvant system , 2007, Expert Review of Vaccines.
[2] T. Kündig,et al. Immunity in response to particulate antigen-delivery systems. , 2005, Advanced drug delivery reviews.
[3] Z. Beck,et al. Detection of liposomal cholesterol and monophosphoryl lipid A by QS-21 saponin and Limulus polyphemus amebocyte lysate. , 2015, Biochimica et biophysica acta.
[4] M. Storgaard,et al. Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial. , 2014, The Journal of infectious diseases.
[5] Harm HogenEsch,et al. Mechanism of Immunopotentiation and Safety of Aluminum Adjuvants , 2013, Front. Immun..
[6] Arnaud M. Didierlaurent,et al. AS04, an Aluminum Salt- and TLR4 Agonist-Based Adjuvant System, Induces a Transient Localized Innate Immune Response Leading to Enhanced Adaptive Immunity1 , 2009, The Journal of Immunology.
[7] Christopher Exley,et al. The immunobiology of aluminium adjuvants: how do they really work? , 2010, Trends in immunology.
[8] J. R. Turner. Efficacy , 2020, Encyclopedia of Behavioral Medicine.
[9] G. Matyas,et al. Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines , 2012, Expert review of vaccines.
[10] J. Tschopp,et al. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome , 2009, Proceedings of the National Academy of Sciences.
[11] I. Carletti,et al. Comparison of the immunogenicity and safety of Cervarix™ and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years , 2009, Human vaccines.
[12] C. Silverman,et al. Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[13] S. Reed,et al. Adjuvants for human vaccines. , 2012, Current opinion in immunology.
[14] G. Leroux-Roels,et al. A hepatitis B vaccine formulated with a novel adjuvant system. , 2000, Vaccine.
[15] N. Andrews,et al. Reactogenicity of Cervarix and Gardasil human papillomavirus (HPV) vaccines in a randomized single blind trial in healthy UK adolescent females , 2017, Human vaccines & immunotherapeutics.
[16] Paul Richman,et al. Aluminum salts in vaccines--US perspective. , 2002, Vaccine.
[17] J. Bryan. Developing an HPV vaccine to prevent cervical cancer and genital warts. , 2007, Vaccine.
[18] M. McElrath,et al. Selection of potent immunological adjuvants for vaccine construction. , 1995, Seminars in cancer biology.
[19] P. Burkhard,et al. Development of a self-assembling protein nanoparticle vaccine targeting Plasmodium falciparum Circumsporozoite Protein delivered in three Army Liposome Formulation adjuvants. , 2017, Vaccine.
[20] G. Keating,et al. Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B. , 2003, Drugs.
[21] Dexiang Chen,et al. Vaccines with aluminum-containing adjuvants: optimizing vaccine efficacy and thermal stability. , 2011, Journal of pharmaceutical sciences.
[22] N. Garçon,et al. Recent clinical experience with vaccines using MPL- and QS-21-containing Adjuvant Systems , 2011, Expert review of vaccines.
[23] N. Waters,et al. Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013. , 2017, Vaccine.
[24] D. Riesner,et al. Sequence-independent Control of Peptide Conformation in Liposomal Vaccines for Targeting Protein Misfolding Diseases* , 2011, The Journal of Biological Chemistry.
[25] M. Amiji,et al. The impact of size on particulate vaccine adjuvants. , 2014, Nanomedicine.
[26] S. Hem,et al. Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation , 2007, Expert review of vaccines.
[27] Z. Beck,et al. Liposomal adjuvants for human vaccines , 2016, Expert opinion on drug delivery.
[28] D. O'hagan,et al. Designing and building the next generation of improved vaccine adjuvants. , 2014, Journal of controlled release : official journal of the Controlled Release Society.
[29] E. Elinav,et al. Integration of Innate Immune Signaling. , 2016, Trends in immunology.
[30] Z. Beck,et al. Differential immune responses to HIV-1 envelope protein induced by liposomal adjuvant formulations containing monophosphoryl lipid A with or without QS21. , 2015, Vaccine.
[31] J. Muderhwa,et al. Oil-in-water liposomal emulsions for vaccine delivery. , 2003, Methods in enzymology.
[32] N. Michael,et al. Heroin-HIV-1 (H2) vaccine: induction of dual immunologic effects with a heroin hapten-conjugate and an HIV-1 envelope V2 peptide with liposomal lipid A as an adjuvant , 2017, npj Vaccines.
[33] R. Coffman,et al. Vaccine adjuvants: putting innate immunity to work. , 2010, Immunity.
[34] J. Deschamps,et al. Efficacy, but not antibody titer or affinity, of a heroin hapten conjugate vaccine correlates with increasing hapten densities on tetanus toxoid, but not on CRM197 carriers. , 2015, Bioconjugate chemistry.